Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
Launched by ABBVIE · Aug 9, 2022
Trial Information
Current as of October 15, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a medication called upadacitinib (brand name RINVOQ) for treating adults with ulcerative colitis (UC), a condition that causes inflammation and bleeding in the large intestine. About 400 adults from Germany, Austria, and Switzerland who are already prescribed upadacitinib will participate in this study. The aim is to see how well the medication works in reducing the symptoms of UC over a period of up to two years.
To be eligible for this trial, participants need to have a confirmed diagnosis of moderate to severe active ulcerative colitis and must be starting treatment with upadacitinib as determined by their doctor. Participants should also be able to communicate with the study staff and agree to continue providing information even after stopping the medication if necessary. Throughout the study, participants will have regular visits to their healthcare provider, but there will be no additional burdens beyond their usual care. This trial is currently recruiting participants, and it’s important to note that those with certain health issues or previous exposure to similar medications may not qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants with an endoscopically confirmed diagnosis of active moderate to severe Ulcerative colitis (UC).
- • Participants initiating Upadacitinib (UPA) at the investigator's discretion as part of their routine clinical care; the decision to administer UPA must be made prior to and independent of documentation for the study and according to the approved local label.
- • Participants able to understand and communicate with the investigator and comply with the requirements of the study.
- • Participants willing to continue with study documentation after cessation of UPA.
- Exclusion Criteria:
- • Participants with any contraindication to Upadacitinib (UPA).
- • Participants previously exposed to a Janus kinase (JAK) inhibitor.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Baden Wuerttemberg, Germany
Herne, Nordrhein Westfalen, Germany
Friedrichsthal, Saarland, Germany
Saarbrücken, Saarland, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Dresden, Germany
Hettstedt, Germany
Karlsruhe, Germany
Kassel, Germany
Koblenz, Germany
Koblenz, Germany
Pirmasens, Germany
Potsdam, Germany
Tostedt, Germany
Berlin, Germany
Berlin, Germany
Bitterfeld Wolfen, Germany
Coesfeld, Germany
Erfurt, Germany
Frechen, Germany
Hamm, Germany
Kiel, Germany
Lübeck, Germany
Minden, Germany
Muenster, Germany
Oldenburg, Germany
Büdelsdorf, Schleswig Holstein, Germany
Berlin Zehlendorf, Germany
Berlin, Germany
Dachau, Germany
Freiburg Im Breisgau, Germany
Geldern, Germany
Hamburg, Germany
Hannover, Germany
Herne, Germany
Iserlohn, Germany
Kiel, Germany
Lueneburg, Germany
Magdeburg, Germany
Muenster, Germany
Rostock, Germany
Schmalkalden, Germany
Stuttgart, Germany
Frankfurt Am Main, Hessen, Germany
Frankfurt, Germany
Halle (Saale), Germany
Nuernberg, Germany
Vienna, Wien, Austria
Cologne, Nordrhein Westfalen, Germany
Lübeck, Schleswig Holstein, Germany
Lübeck, Schleswig Holstein, Germany
Jena, Thueringen, Germany
Jena, Thueringen, Germany
Altenholz, Germany
Darmstadt, Germany
Dresden, Germany
Dresden, Germany
Hannover, Germany
Schwerin, Germany
Salzburg, Austria
Altenholz, Schleswig Holstein, Germany
Brandenburg An Der Havel, Brandenburg, Germany
Blaubeuren, Germany
Leverkusen, Germany
Munich, Germany
Leipzig, Sachsen, Germany
Augsburg, Germany
Frankfurt, Germany
Heinsberg, Germany
Jena, Germany
Munich, Germany
Nürtingen, Germany
Würselen, Germany
Munich, Germany
Linz, Oberoesterreich, Austria
Heidelberg, Baden Wuerttemberg, Germany
Chemnitz, Germany
Solingen, Germany
Potsdam, Brandenburg, Germany
Leipzig, Sachsen, Germany
Berlin, Germany
Heilbronn, Germany
Jerichow, Germany
Linz, Oberoesterreich, Austria
Kassel, Germany
Neumuenster, Schleswig Holstein, Germany
Munich, Germany
Rostock, Mecklenburg Vorpommern, Germany
Worms, Rheinland Pfalz, Germany
Chemnitz, Saarland, Germany
Dachau, Saarland, Germany
Darmstadt, Saarland, Germany
Frankfurt, Saarland, Germany
Frankfurt, Saarland, Germany
Hannover, Saarland, Germany
Kassel, Saarland, Germany
Kiel, Saarland, Germany
Kiel, Saarland, Germany
Koblenz, Saarland, Germany
Lueneburg, Saarland, Germany
Minden, Saarland, Germany
Oldenburg, Saarland, Germany
Augsburg, Bayern, Germany
Wuppertal, Nordrhein Westfalen, Germany
Dachau, Bayern, Germany
Darmstadt, Hessen, Germany
Frankfurt, Hessen, Germany
Frankfurt, Hessen, Germany
Kassel, Hessen, Germany
Hannover, Niedersachsen, Germany
Lueneburg, Niedersachsen, Germany
Oldenburg, Niedersachsen, Germany
Minden, Nordrhein Westfalen, Germany
Koblenz, Rheinland Pfalz, Germany
Chemnitz, Sachsen, Germany
Dresden, Sachsen, Germany
Kiel, Schleswig Holstein, Germany
Kiel, Schleswig Holstein, Germany
Zurich, Zuerich, Switzerland
Zurich, Zuerich, Switzerland
Bern, Switzerland
Bern, Switzerland
Ludwigshafen Am Rhein, Rheinland Pfalz, Germany
Lübeck, Schleswig Holstein, Germany
Darmstadt, Hessen, Germany
Jerichow, Sachsen Anhalt, Germany
Kiel, Schleswig Holstein, Germany
Hamburg, Germany
Munich, Bayern, Germany
Hannover, Niedersachsen, Germany
Coesfeld, Nordrhein Westfalen, Germany
Chemnitz, Sachsen, Germany
Leipzig, Sachsen, Germany
Altenholz, Schleswig Holstein, Germany
Hanau, Germany
Lugano, Ticino, Switzerland
Zurich, Zuerich, Switzerland
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials